In April 2010, DSP's original U.S. subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA) was merged into Sepracor. Sunovion is the new company born of this union.

Sunovion is a leading pharmaceutical company dedicated to discovering, developing, and bringing to market therapeutic products that advance the science of medicine to improve the lives of patients, their families, and communities. We specialize in treatments that help people challenged by disorders of the central nervous system and respiratory ailments.

We are developing products with our own internal development programs and collaborating with outside partners on various corporate development and licensing arrangements.

Between our current treatments and the products in our pipeline, Sunovion targets, on the one hand, central nervous system disorder such as schizophrenia, depression, epilepsy, neuropathic pain, and insomnia, and on the other, respiratory conditions such as asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD).

Our products are the result of different approaches: our own in-house drug development programs; refining existing products to enhance their safety and efficacy profiles resulting in unique new medicines; along with strategic acquisition and so-called in-licensing of products developed by others.